INVESTIGATION INTO THE USE OF SUNGATE CONCLUDES

07 Aug 2013 Pre-2014 Releases

The British Horseracing Authority (BHA) has today announced the conclusion of the investigation into the use of Sungate, a veterinary product which contains stanozolol, an anabolic steroid and therefore a prohibited substance under the Rules of Racing.

The relevant trainers interviewed as part of the investigation have been informed that the BHA has concluded that no charges under the Rules of Racing will be issued against them.

The BHA became aware of the nature of Sungate and its use on horses in training following a visit to Gerard Butler’s yard in February 2013 as part of its testing in training sampling programme, from which nine horses produced positive tests for stanozolol. It became apparent that a veterinary practice, which had legally imported Sungate under licence into the UK, was prescribing this product and had recommended its initial administration to horses in training.

The BHA subsequently met with representatives of the veterinary practice in question. As a result of that meeting the BHA became aware that Gerard Butler was not the only trainer to whom it was recommended that Sungate be administered to horses in the trainer’s care.

Upon becoming aware of the nature of and use of the product on horses in training the BHA notified the NTF of the product’s name and that it contained a prohibited substance. The NTF subsequently distributed this information to all of their members.

In order to establish the extent of the use of the product, the BHA identified and met with 38 trainers who were known to use the same veterinary practice.

The investigation identified that 43 horses from nine trainers had been treated with Sungate by veterinary surgeons and on veterinary advice since early 2010. These administrations were recorded in the medication records required to be kept by trainers in accordance with the Rules, and in the clinical histories of the horses which were obtained, with the trainers’ consent, from the veterinary practice.

Based on the information gathered during the investigation the BHA concluded that there are no grounds for charges to be brought.

Adam Brickell, Director of Integrity, Legal and Risk for the BHA, said:

“Having carefully considered our options under the Rules, including taking legal advice and reviewing previous cases, we have concluded that there would no reasonable prospect of a Disciplinary Panel finding that these trainers have breached the Rules of Racing.

“Under the current Rules of Racing, in the absence of any positive samples, charges could only be brought in cases such as this if there is evidence that the trainer concerned has acted in a manner prejudicial to the integrity, proper conduct, or good reputation of the sport. In these cases there was no such evidence. This is because the nine trainers in question only allowed their horses to be administered with the product on the advice of – and by – veterinary surgeons to treat orthopaedic conditions.

“Following the completion of this investigation, and the ongoing disciplinary proceedings involving Gerard Butler, consideration will be given as to whether the current Rules provide sufficient and appropriate protection against the type of scenario highlighted in this case. In addition, while acknowledging that veterinary surgeons are not currently accountable to the BHA, we will consider how we can reduce the risk of incidents such as this happening again.

“The charges brought against Gerard Butler are based on a different set of facts and circumstances to those which were identified during this investigation. A date for this hearing will be announced in due course.

“Meanwhile, all licensed trainers are reminded that if a prohibited substance is found to be present in the system of any horse under their care or control, that would constitute a breach of the Rules of Racing. They are also reminded that it is their responsibility as licensed trainers to be familiar with the Rules that govern which substances can and cannot be given to horses under their care and control.

“Due to the number of individuals and horses involved, and the volume of records reviewed, the process to ascertain the extent to which this product has been used has necessarily been a lengthy one. However we acknowledge that the cooperation of the trainers in this investigation has made the process less difficult than it might have been.”

Jenny Hall, Interim Chief Veterinary Officer for the BHA, said:

“It is important to note that the product at the centre of this investigation is a treatment designed to be injected into a horse’s joints, and is very different to that which might be used in an intramuscular anabolic steroid product.

“The recommended dose of Sungate varies according to the size of the joint to be treated, but a typical intra-muscular injectable anabolic steroid product has around ten times the concentration of anabolic agent compared to Sungate, and a recommended dosage would generally contain around fifty times the volume of anabolic agent administered in one Sungate treatment.

“In addition, it follows that when a veterinary product has been used to treat an orthopaedic condition there is a recovery period associated with the treatment before a horse can return to the racecourse. The clinical histories of the horses in question confirmed that in each case where Sungate had been administered by veterinary surgeons it had indeed been done so to treat an orthopaedic condition.

“However, it remains a matter of serious concern that a veterinary practice recommended and administered a product containing anabolic steroids, which are prohibited substances under the Rules of Racing, to these horses.”

Notes to Editors:

1. Sungate is a product developed by an Italian company, produced and licensed for equine use in Italy. Its use in the UK is legal, but only when imported under the Special Import Certificate scheme administered by the Veterinary Medicines Directorate.

2. The recommended dose of Sungate varies according to the size of the joint to be treated but the manufacturer states it should never exceed 5mg of stanozolol in a 1ml suspension in medium-sized joints.

A typical intra-muscular injectable stanozolol product, meanwhile, contains 50mg of stanozolol per 1ml, so is ten times the strength of Sungate, and the recommended dose for an average sized thoroughbred is 5ml – so 250mg of stanozolol, or 50 times the dose compared to Sungate.

3. No charges have been brought against any trainers involved in this case. As such it is the policy of the BHA that those trainers we have spoken to should not be named, as would be the case with any investigation from which no charges are brought.

The same policy extends to the horses involved as naming the horses would subsequently name the trainers.

4. The Rules also do not provide for a horse to be disqualified from any race it participated in subsequent to the administration of a prohibited substance unless there are the analytical results of a sample showing such substance was present in the horse at the time of the race.

5. Details of the charges being brought against Gerard Butler can be found here:
http://www.britishhorseracing.com/press_releases/notice-of-a-forthcoming-disciplinary-panel-hearing-gerard-butler/

For more information contact:

Robin Mounsey
British Horseracing Authority
t: 0207 252 0048
m: 07584 171551
e: rmounsey@britishhorseracing.com